Desmopressin melt improves response and compliance compared with tablet in treatment of primary monosymptomatic nocturnal enuresis

Kristian Vinter Juul, Charlotte Van Herzeele, Pauline De Bruyne, Sandra Goble, Johan Vande Walle, Jens Peter Nørgaard, Kristian Vinter Juul, Charlotte Van Herzeele, Pauline De Bruyne, Sandra Goble, Johan Vande Walle, Jens Peter Nørgaard

Abstract

Primary nocturnal enuresis is a prevalent childhood condition that can persist into adulthood. Desmopressin is an antidiuretic available as orally disintegrating lyophilisate (melt) or solid tablet. Recent findings suggesting different food interactions and clinical characteristics, including compliance, between desmopressin melt and tablet motivated a post hoc analysis of a previously reported randomised, crossover study. The efficacy of desmopressin melt compared with tablet was evaluated using the International Children's Continence Society (ICCS) responder definitions. Compliance was further analysed using detailed criteria, and the association between efficacy and compliance was examined. In total, 221 patients aged 5-15 years, already receiving desmopressin tablets were randomised to the treatment sequence melt (120/240 μg)/tablet (0.2/0.4 mg) or tablet/melt in two consecutive 3-week periods. The probability of being a responder (partial or full) during either period was significantly more likely with desmopressin melt compared with tablet (odds ratio, 2.0; confidence intervals, 1.07-3.73; p = 0.03). There was no period effect on compliance in the tablet/melt sequence and no difference in the number of completely compliant patients in each formulation group; however, more patients were >75 % compliant in period 1 compared with period 2 in the melt/tablet sequence. Increased compliance was associated with greater reductions in the number of wet nights for both formulations.

Conclusions: Desmopressin melt, compared with tablet, improves the probability of being a responder. Switching from tablet to melt formulation increased patient compliance. Increased compliance was associated with increased efficacy. Switching to desmopressin melt may benefit patients with suboptimal responses to desmopressin tablet.

Trial registration: ClinicalTrials.gov NCT00209261.

Figures

Fig. 1
Fig. 1
Study design. Patients stabilised on 0.2 or 0.4 mg desmopressin tablets entered a 2-week screening period. Eligible patients were randomised 1:1 to receive melt or tablet for 3 weeks, then switched to the alternative formulation for 3 weeks
Fig. 2
Fig. 2
Comparison between compliance groups on the reduction in mean number of wet nights, overall across formulations. *p≤0.05, statistically significant difference between compliance groups

References

    1. De Guchtenaere A, Hoebeke P, Van Herzeele C, Dehoorne J, Raes A, Van Laecke E, De Bruyne P, Vande Walle J (2011) Pharmacokinetic characteristics of desmopressin oral lyophilisate (MELT) and tablet formulation in children. Neurourol Urodyn 30: Abstract 163
    1. De Guchtenaere A, Van Herzeele C, Raes A, Dehoorne J, Hoebeke P, Van Laecke E, Vande WJ. Oral lyophylizate formulation of desmopressin: superior pharmacodynamics compared to tablet due to low food interaction. J Urol. 2011;185:2308–2313. doi: 10.1016/j.juro.2011.02.039.
    1. De Guchtenaere A, Raes A, Vande Walle C, Hoebeke P, Van Laecke E, Donckerwolcke R, Vande WJ. Evidence of partial anti-enuretic response related to poor pharmacodynamic effects of desmopressin nasal spray. J Urol. 2009;181:302–309. doi: 10.1016/j.juro.2008.09.040.
    1. Dhondt K, Raes A, Hoebeke P, Van Laecke E, Van Herzeele C, Vande WJ. Abnormal sleep architecture and refractory nocturnal enuresis. J Urol. 2009;182(Suppl 4):1961–1965. doi: 10.1016/j.juro.2009.05.103.
    1. Hjalmas K, Arnold T, Bower W, Caione P, Chiozza LM, von Gontard A, Han SW, Husman DA, Kawauchi A, Lackgren G, Lottmann H, Mark S, Rittig S, Robson L, Walle JV, Yeung CK. Nocturnal enuresis: an international evidence based management strategy. J Urol. 2004;171:2545–2561. doi: 10.1097/01.ju.0000111504.85822.b2.
    1. Läckgren G, Lilja B, Nevèus T, Stenberg A. Desmopressin in the treatment of severe nocturnal enuresis in adolescents—a 7-year follow-up study. Br J Urol. 1998;81(Suppl 3):17–23.
    1. Lottmann H, Froeling F, Alloussi S, El-Rhadi A, Rittig S, Riis A, Persson BE. A new oral MELT formulation of desmopressin in primary nocturnal enuresis (PNE). A randomized comparison to the tablet formulation. Poster presented at EAU, 5–8 April 2006, Paris. Abstract 1122
    1. Lottmann H, Baydala L, Eggert P, Klein BM, Evans J, Nørgaard JP. Long-term desmopressin response in primary nocturnal enuresis: open-label, multinational study. Int J Clin Pract. 2009;63:35–45. doi: 10.1111/j.1742-1241.2008.01956.x.
    1. Lottmann H, Froeling F, Alloussi S, El-Radhi AS, Rittig S, Riis A, Persson BE. A randomised comparison of oral desmopressin lyophilisate (MELT) and tablet formulations in children and adolescents with primary nocturnal enuresis. Int J Clin Pract. 2007;61:1454–1460. doi: 10.1111/j.1742-1241.2007.01493.x.
    1. Nevéus T, von Gontard A, Hoebeke P, Hjälmås K, Bauer S, Bower W, Jørgensen TM, Rittig S, Walle JV, Yeung CK, Djurhuus JC. The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children's Continence Society. J Urol. 2006;176:314–324. doi: 10.1016/S0022-5347(06)00305-3.
    1. Osterberg O, Savic RM, Karlsson MO, Simonsson US, Nørgaard JP, Walle JV, Agersø H. Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults. J Clin Pharmacol. 2006;46:1204–1211. doi: 10.1177/0091270006291838.
    1. Rittig S, Schaumburg HL, Siggaard C, Schmidt F, Djurhuus JC. The circadian defect in plasma vasopressin and urine output is related to desmopressin response and enuresis status in children with nocturnal enuresis. J Urol. 2008;179:2389–2395. doi: 10.1016/j.juro.2008.01.171.
    1. Robson L. Bedwetting. Parkhurst Exchange. 2007;15:66–67.
    1. Tekgul S, Nijman R, Hoebeke P, Canning D, Bower W, von Gontard A. Diagnosis and management of urinary incontinence in childhood. Report from the 4th International Consultation on Incontinence. . Accessed September 2012
    1. Theunis M, Van Hoecke E, Paesbrugge S, Hoebeke P, Vande WJ. Self-image and performance in children with nocturnal enuresis. Eur Urol. 2002;41:660–667. doi: 10.1016/S0302-2838(02)00127-6.
    1. Van Herzeele C, Alova I, Evans J, Eggert P, Lottmann H, Nørgaard JP, Vande WJ. Poor compliance with primary nocturnal enuresis therapy may contribute to insufficient desmopressin response. J Urol. 2009;182(Suppl 4):2045–2049. doi: 10.1016/j.juro.2009.06.001.
    1. Vande Walle J, Rittig S, Bauer S, Eggert P, Marschall-Kehrel D, Tekgul S. Practical consensus guidelines for the management of enuresis. Eur J Pediatr. 2012;171:971–983. doi: 10.1007/s00431-012-1687-7.
    1. Vande WJ, Van Laecke E. Pitfalls in studies of children with monosymptomatic nocturnal enuresis. Pediatr Nephrol. 2008;23:173–178. doi: 10.1007/s00467-007-0688-7.
    1. Vande Walle J, Van Herzeele C, Raes A. Is there still a role for desmopressin in children with primary monosymptomatic nocturnal enuresis? A focus on safety issues. Drug Saf. 2010;33:261–271. doi: 10.2165/11319110-000000000-00000.
    1. Vande Walle JG, Bogaert GA, Mattsson S, Schurmans T, Hoebeke P, Deboe V, Nørgaard JP. A new fast-melting oral formulation of desmopressin: a pharmacodynamic study in children with primary nocturnal enuresis. BJU Int. 2006;97:603–609. doi: 10.1111/j.1464-410X.2006.05999.x.
    1. Yeung CK, Sreedhar B, Sihoe JD, Sit FK, Lau J. Differences in characteristics of nocturnal enuresis between children and adolescents: a critical appraisal from a large epidemiological study. BJU Int. 2006;97:1069–1073. doi: 10.1111/j.1464-410X.2006.06074.x.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi